Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05227404 · ClinicalTrials.gov registry record
Evaluation of Point-of-Care (EPOC) for COVID-19
A clinical trial, sponsored by University of Minnesota.
- Completed
- Registry status
- 330
- Enrollment target
NCT05227404 is a clinical trial that has completed, run by University of Minnesota. The registered enrollment target is 330 participants.
The verdict
NCT05227404 has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- 330 participants
- Enrollment target
Study Summary
EPOC is designed to examine the feasibility of conducting two point-of-care (POC) tests the LumiraDx SARS-CoV-2 Antibody Test and the RightSign COVID-19 IgG/IgM Rapid Test for SARS-CoV-2 antibodies and compare the reproducibility of these tests to tests run at a central laboratory on specimens obtained from the same study participants at the same time.
Interventions
- DIAGNOSTIC_TEST LumiraDX
- DIAGNOSTIC_TEST RightSign
- DIAGNOSTIC_TEST Case Control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2022-04-08 |
| Est. Completion | 2022-09-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05227404
The ClinicalTrials.gov registry entry for NCT05227404 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which LumiraDX is the first listed.
NCT05227404 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05227404 about?
NCT05227404 is a clinical study titled "Evaluation of Point-of-Care (EPOC) for COVID-19". EPOC is designed to examine the feasibility of conducting two point-of-care (POC) tests the LumiraDx SARS-CoV-2 Antibody Test and the RightSign COVID-19 IgG/IgM Rapid Test for SARS-CoV-2 antibodies and compare the reproducibility of these tests to tests run at a central laboratory on specimens obtai...
What is the current status of trial NCT05227404?
This trial is currently completed. The enrollment target is 330 participants. The study started on 2022-04-08. Estimated completion is 2022-09-02.
What interventions are being tested in trial NCT05227404?
The interventions under investigation include: LumiraDX (DIAGNOSTIC_TEST), RightSign (DIAGNOSTIC_TEST), Case Control (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05227404?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.